177 Lutetium Psma 617 Emerging Drug Insight And Market Forecast
“177-LUTETIUM-PSMA-617- Emerging Drug Insight and Market Forecast – 2030” the report provides comprehensive insights about an investigational product for Prostate cancer in 7 Major Markets. A detailed picture of the 177-LUTETIUM-PSMA-617 in Seven Major Markets, i.e., United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan, for the study period 2020–2030 is provided in this report along with a detailed description of the product. The product details cover mechanism of action, dosage and administration, route of synthesis, and Research and development activity including regulatory milestones, and other development activities. Further, it also consists of future market assessments inclusive of the market forecast, SWOT analysis, market competitors, and other emerging therapies.
Lu-PSMA is an experimental drug, a type known as a radiopharmaceutical. The 177lutetium is a radionuclide (radioactive isotope) (the warhead), while the PSMA-617 is a peptide delivering the warhead to cancer cells (the missile). Lu-PSMA is part of an emerging field of cancer therapy known as theranostics, not the easiest word to get your mind around, but one that you are going to hear a lot more about in the coming years. Lu-PSMA is injected intravenously.
The purpose is to deliver radioactivity directly to all prostate cancer cells in the body in men with late-stage, metastatic prostate cancer, something that is not possible with externally delivered radiation which needs to be focused just on small areas of the body. Lu-PSMA targets a protein displayed on the surface of prostate cancer cells known as prostate-specific membrane antigen (PSMA). The PSMA-617 part of the drug seeks out this protein. The 177lutetium part of the drug delivers the damage which hopefully slows down or even kills the cancer cell. About 90% of men express PSMA and are suitable for Lu-PSMA treatment.
Scope of the report
The report provides insights into:
- A comprehensive product overview including the product description, mechanism of action, dosage and administration, Research and Development activity.
- Elaborated details on regulatory milestones and other development activities have been provided in this report.
- The report also highlights the drug research and development activity details across the United States, Europe and Japan.
- The report also covers the patents information with expiry timeline around 177-LUTETIUM-PSMA-617.
- The report contains forecasted sales for 177-LUTETIUM-PSMA-617 till 2030.
- Comprehensive coverage of the late-stage emerging therapies (Phase III) for Prostate cancer.
- The report also features the SWOT analysis with analyst insights and key findings of 177-LUTETIUM-PSMA-617.
The report is built using data and information sourced primarily from internal databases, primary and secondary research and in-house analysis by DelveInsight’s team of industry experts. Information and data from the secondary sources have been obtained from various printable and nonprintable sources like search engines, news websites, global regulatory authorities websites, trade journals, white papers, magazines, books, trade associations, industry associations, industry portals and access to available databases.
177-LUTETIUM-PSMA-617 Analytical Perspective by DelveInsight
- In-depth 177-LUTETIUM-PSMA-617 Market Assessment
This report provides a detailed market assessment of 177-LUTETIUM-PSMA-617 in Seven Major Markets, i.e., United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan. This segment of the report provides forecasted sales data from 2020 to 2030.
- 177-LUTETIUM-PSMA-617 Clinical Assessment
The report provides the clinical trials information of 177-LUTETIUM-PSMA-617 covering trial interventions, trial conditions, trial status, start and completion dates.
- In the coming years, the market scenario for Prostate cancer is set to change due to the extensive research and incremental healthcare spending across the world; which would expand the size of the market to enable the drug manufacturers to penetrate more into the market.
- The companies and academics are working to assess challenges and seek opportunities that could influence 177-LUTETIUM-PSMA-617 dominance. The therapies under development are focused on novel approaches to treat/improve the disease condition.
- Other emerging products for Prostate cancer are giving market competition to 177-LUTETIUM-PSMA-617 and launch of late-stage emerging therapies in the near future will significantly impact the market.
- A detailed description of regulatory milestones, development activities, and some key findings provide the current development scenario of 177-LUTETIUM-PSMA-617.
- Our in-depth analysis of the forecasted sales data of 177-LUTETIUM-PSMA-617 from 2020 to 2030 will support the clients in the decision-making process regarding their therapeutic portfolio by identifying the overall scenario of the 177-LUTETIUM-PSMA-617.
- Which company is developing 177-LUTETIUM-PSMA-617 along with the phase of the clinical study?
- What is the technology utilized in the development of 177-LUTETIUM-PSMA-617?
- What is the product type, route of administration and mechanism of action of 177-LUTETIUM-PSMA-617?
- What is the clinical trial status of the study and study completion date?
- What are the key collaborations, mergers and acquisitions, licensing and other activities related to the 177-LUTETIUM-PSMA-617 development?
- What are the key designations that have been granted to 177-LUTETIUM-PSMA-617?
- What is the forecasted market scenario of 177-LUTETIUM-PSMA-617?
- What is the history of 177-LUTETIUM-PSMA-617 and what is its future?
- What is the forecasted sales of 177-LUTETIUM-PSMA-617 in the seven major countries, including the United States, Europe (Germany, France, Italy, Spain, and the United Kingdom), and Japan?
- What are the other emerging products available and how these are giving competition to 177-LUTETIUM-PSMA-617?
- Which are the late-stage emerging therapies under development for the treatment of the PPD?